Podcast
Play an AI-generated podcast conversation about this lesson
Questions and Answers
Which factor was significantly reduced by all DOACs in the phase III trials compared with warfarin?
Which factor was significantly reduced by all DOACs in the phase III trials compared with warfarin?
- Cardioembolic stroke
- Thrombotic stroke
- Ischemic stroke (correct)
- Hemorrhagic stroke
In which patients should dabigatran be avoided according to the phase III trials?
In which patients should dabigatran be avoided according to the phase III trials?
- Patients with a history of hemorrhagic stroke
- Patients with a CHADS 2 score less than 3 (correct)
- Patients with a CHADS 2 score of 3 or more
- Patients with a history of ischemic stroke
Which of the following statements is true about the effectiveness of apixaban and rivaroxaban?
Which of the following statements is true about the effectiveness of apixaban and rivaroxaban?
- Apixaban was superior to warfarin in the ARISTOTLE trial (correct)
- Rivaroxaban was significantly better than apixaban in reducing stroke risk
- Apixaban was only noninferior to warfarin in the ARISTOTLE trial
- Rivaroxaban was superior to warfarin in the ROCKET-AF trial
Which DOAC showed superiority in reducing stroke risk compared to warfarin in its respective trial?
Which DOAC showed superiority in reducing stroke risk compared to warfarin in its respective trial?
Signup and view all the answers
